role of the vegf inhibitor aflibercept in metastatic colorectal cancer
Published 10 years ago • 972 plays • Length 6:26Download video MP4
Download video MP3
Similar videos
-
0:53
dr. chan discusses the vegf-trap agent aflibercept
-
18:58
mechanisms of angiogenesis inhibitors in metastatic colorectal cancer
-
10:02
role of the multikinase inhibitor regorafenib in metastatic colorectal cancer
-
2:29
aflibercept plus folfiri in polish patients with metastatic colorectal cancer
-
6:32
antiangiogenic therapy for metastatic colorectal cancer
-
1:05
dr. peeters on the utility of aflibercept in advanced colorectal cancer
-
13:11
treatment sequencing in metastatic colorectal cancer
-
41:03
part 1: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer
-
7:11
the genetics of metastatic colorectal cancer
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
8:41
use of vegf-targeted tyrosine kinase inhibitors
-
1:18
dr. richard kim on administering aflibercept in colorectal cancer
-
5:36
pathways of resistance in metastatic colorectal cancer
-
10:49
part 3: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
3:02
final thoughts on the treatment of metastatic colorectal cancer
-
6:42
novel therapies in development for metastatic colorectal cancer
-
4:24
the current paradigm of metastatic colorectal cancer
-
5:54
initial systemic therapy for metastatic colorectal cancer